Magic mushroom compound shows promise for Hard-to-Treat depression and suicidal thoughts
NCT ID NCT05220410
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a single 25mg dose of psilocybin in 20 adults with depression that didn't respond to standard treatments and who also had ongoing suicidal thoughts. The goal was to see if the drug is safe and tolerable in this high-risk group. Participants received the dose in a supportive setting, and researchers measured changes in suicidal thinking and depression severity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SUICIDAL IDEATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sheppard Pratt Health System
Baltimore, Maryland, 21204, United States